Sandoz Launches Generic Lovenox
This article was originally published in The Pink Sheet Daily
Executive Summary
Sandoz has a monopoly on the generic enoxaparin market for now, but Teva insists its ANDA is progressing at FDA.
You may also be interested in...
Momenta, Sandoz Play Patent Defense For A Change, Seek Injunction To Prevent Teva From Launching Generic Lovenox
Firms claim Teva, which now seems close to approval, cannot manufacture enoxaparin to match Sanofi's branded Lovenox without infringing Momenta's manufacturing process.
Momenta, Sandoz Play Patent Defense For A Change, Seek Injunction To Prevent Teva From Launching Generic Lovenox
Firms claim Teva, which now seems close to approval, cannot manufacture enoxaparin to match Sanofi's branded Lovenox without infringing Momenta's manufacturing process.
Sanofi Holds Its Ground On Genzyme Bid
CEO Viehbacher defended Sanofi's $69-per-share hostile bid for Genzyme while reporting third quarter financial results -- even as the French Pharma took a hit from generic Lovenox.